Indoco Remedies

Indoco Remedies Equity

The The Equity of Indoco Remedies (INDOCO.NS) as of Oct 16, 2026 is 9.39 B INR. In the previous year, The Equity was 10.22 B INR — a change of -8.09% (lower).

Equity

9.39 BINR

YoY

-8.09%

Last updated:

In 2026, Indoco Remedies's equity was 9.39 B INR, a -8.09% increase from the 10.22 B INR equity in the previous year.

The Indoco Remedies Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
6.61 B INR
Jan 1, 2020
6.80 B INR
Jan 1, 2021
7.69 B INR
Jan 1, 2022
9.05 B INR
Jan 1, 2023
10.28 B INR
Jan 1, 2024
11.10 B INR
Jan 1, 2025
10.22 B INR
Jan 1, 2026
9.39 B INR
The Indoco Remedies Equity history
YEAREquityYoY
9.39 BINR-8.09%
10.22 BINR-7.92%
11.10 BINR+7.94%
10.28 BINR+13.66%
9.05 BINR+17.64%
7.69 BINR+13.16%
6.80 BINR+2.87%
6.61 BINR-2.13%
6.75 BINR+3.60%
6.52 BINR+11.51%
5.84 BINR+12.63%
5.19 BINR+13.49%
4.57 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Indoco Remedies's Equity

Indoco Remedies's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Indoco Remedies's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Indoco Remedies's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Indoco Remedies's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Indoco Remedies’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Indoco Remedies stock

The Equity of Indoco Remedies is 9.39 B INR in 2026.

The Equity of Indoco Remedies changed from 10.22 B INR to 9.39 B INR, representing a -8.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Indoco Remedies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Indoco Remedies

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Indoco Remedies